What happened with ANIK today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Anika Therapeutics makes Monovisc and Orthovisc, injections that use hyaluronic acid to relieve osteoarthritis pain. Doctors generally administer them in their offices; U.S. labeling permits knee use only. Anika supplies both products exclusively to Johnson & Johnson MedTech (J&J MedTech) in the United States, receiving payments for the products and royalties on J&J MedTech’s sales. Sales through commercial partners generate most of Anika’s revenue. J&J MedTech is its largest customer and controls U.S. pricing, marketing and distribution, making Anika heavily dependent on that relationship. J&J MedTech has announced plans to divest the business that includes these products.
Outside the United States, distributors buy Anika’s osteoarthritis products and handle local sales and marketing. These include Cingal, which combines hyaluronic acid with a steroid for pain relief. Cingal is sold internationally but is not approved for commercial use in the United States; Anika is pursuing FDA approval.
Anika also sells products used in tissue repair, including Integrity for tendon repairs and Hyalofast for cartilage repair. It sells its U.S. regenerative products to clinicians, hospitals and ambulatory surgery centers through its sales team and independent distributors. Hyalofast is sold outside the United States but remains under FDA review and is not commercially available there. Product use also depends on insurance coverage and reimbursement: providers purchase products and then seek payment from insurers, so payment restrictions or denials can discourage use.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Anika’s results hinge on J&J MedTech’s purchasing and pricing, reimbursement for osteoarthritis treatments, and adoption of its regenerative products against rivals including privately held Arthrex.
Anika depends heavily on Johnson & Johnson MedTech, which buys its Monovisc and Orthovisc knee-pain injections exclusively for sale to U.S. end users and accounted for half of Anika’s 2025 product revenue. Watch its purchase prices and volumes: Anika’s revenue from this customer fell $12.6 million in 2025, mostly because of lower pricing.
Bioventus competes with Anika for knee osteoarthritis pain treatments and bone-repair products. Its knee-pain and bone-graft-substitute sales are the relevant businesses to watch alongside Anika’s pain injections and Tactoset bone substitute, rather than its wider surgical portfolio.
Zimmer Biomet challenges Anika in both osteoarthritis pain treatment and regenerative orthopedic care, selling products that treat damaged bones, joints and supporting soft tissues. Its sports-medicine and biologic product developments are worth watching against Anika’s tendon- and cartilage-repair products.
Pacira BioSciences competes with Anika in osteoarthritis pain treatment, but its ZILRETTA business is a closer comparison than EXPAREL, its larger postsurgical anesthetic business. Watch ZILRETTA sales rather than Pacira’s total revenue when assessing competition for Anika’s pain treatments.
Sanofi competes with Anika in osteoarthritis pain management through Sanofi Genzyme, although its medicines and vaccines span far more diseases. For Anika holders, Sanofi Genzyme’s osteoarthritis treatment news matters more than Sanofi’s broader vaccine business.
Smith & Nephew competes with Anika’s regenerative products for orthopedic tissue repair, selling medical technologies to healthcare customers and supporting their clinical and reimbursement needs. Its tissue-repair product launches and clinical evidence are worth watching as Anika builds adoption of Integrity for tendon repair.
CONMED sells orthopedic implants and surgical equipment to surgeons also served by Anika, which explicitly names it as an osteoarthritis pain-management competitor. Its orthopedic surgery sales are the relevant customer-market comparison for Anika’s products sold to hospitals and ambulatory surgery centers, rather than its general surgery sales.
Stryker competes with Anika’s regenerative orthopedic products for surgeons treating musculoskeletal injuries. Watch its Orthopaedics business rather than company-wide sales when comparing the competitive backdrop for Anika’s tendon, cartilage and bone-repair products.
Bioventus Inc. earningsBVS
Bioventus’ report will show sales in knee pain and bone repair, markets where its products compete with Anika Therapeutics’ offerings.
Focus on Bioventus’ knee-pain and bone-graft-substitute sales, not total company revenue. Strength in both would indicate continued demand in markets relevant to Anika’s pain injections and Tactoset, alongside active competition. Weakness could point to a softer market for those products too, but would not establish how Anika itself is selling.
Anika Therapeutics Inc earningsThis company
Anika Therapeutics’ report will show whether growth in its own sales channel can offset weaker OEM business and stabilize gross margin.
Read Commercial Channel revenue alongside OEM Channel revenue and gross margin. If Anika’s own-channel sales keep growing, OEM declines ease, and gross margin stabilizes, the company is reducing reliance on partners while protecting product profitability. If OEM revenue and margin keep weakening and own-channel growth cannot fill the gap, its channel shift is not yet offsetting partner-price and cost pressure.
